Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

Molecular Therapy

Volumn 23, Issue 9, 2015, Pages 1532-1540

  Park, Se Hoon ^a   Breitbach, Caroline J ^b   Lee, Jeeyun ^a   Park, Joon Oh ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a   Moon, Anne ^b,f   Mun, Jae Hee ^c   Sommermann, Erica M ^c   Maruri Avidal, Liliana ^c   Patt, Rick ^d   Pelusio, Adina ^b   Burke, James ^b   Hwang, Tae Ho ^c,e   Kirn, David ^b   Park, Young Suk ^a  

^a Samsung Medical Center   (South Korea)

^b Sillajen Biotherapeutics Inc   (United States)

^c SillaJen Inc   (South Korea)

^d RadMD   (United States)

^e Pusan National University School of Medicine   (South Korea)

^f Aduro BioTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEXASTIMOGENE DEVACIREPVEC; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC VIRUS;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANTIBODY TITER; ARTICLE; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INFUSION RELATED REACTION; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PUSTULE; RASH; STOMATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINIA VIRUS; VOMITING; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROCEDURES; SKIN DISEASES;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SKIN DISEASES; TREATMENT OUTCOME; VACCINIA VIRUS;

EID: 84940721633     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.109     Document Type: Article

References (14)

1. Douillard, JY, Siena, S, Cassidy, J, Tabernero, J, Burkes, R, Barugel, M et al. (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28: 4697-4705.
2. Peeters, M, Price, TJ, Cervantes, A, Sobrero, AF, Ducreux, M, Hotko, Y et al. (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28: 4706-4713.
3. Lièvre, A, Bachet, JB, Le Corre, D, Boige, V, Landi, B, Emile, JF et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
4. Grothey, A, Van Cutsem, E, Sobrero, A, Siena, S, Falcone, A, Ychou, M et al. ; CORRECT Study Group. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 381: 303-312.
5. Parato, KA, Breitbach, CJ, Le Boeuf, F, Wang, J, Storbeck, C, Ilkow, C et al. (2012). The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 20: 749-758.
6. Kim, JH, Oh, JY, Park, BH, Lee, DE, Kim, JS, Park, HE et al. (2006). Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370.
7. Park, BH, Hwang, T, Liu, TC, Sze, DY, Kim, JS, Kwon, HC et al. (2008). Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol 9: 533-542.
8. Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19: 329-336.
9. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
10. Hovgaard, D, Mortensen, BT, Schifter, S and Nissen, NI (1992). Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur J Clin Invest 22: 45-49.
11. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751-8757.
12. Kirn, DH, Wang, Y, Liang, W, Contag, CH and Thorne, SH (2008). Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res 68: 2071-2075.
13. Heinemann, L, Simpson, GR, Boxall, A, Kottke, T, Relph, KL, Vile, R et al. (2011). Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 11: 221.
14. Liu, TC, Hwang, T, Park, BH, Bell, J and Kirn, DH (2008). The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 16: 1637-1642.